SocialDiabetes, the digital solution for diabetes management
The best tools, on a single platform
Simplifying diabetes management
Our goal is to improve the quality of life for people with diabetes and optimize outcomes for patients and healthcare professionals. We are patients working for patients, creating a system that synchronizes with multiple devices and provides relevant information for decision making in one place.
simplify_diabetes_management
Simplifying management
The information registered by the patient in his APP is updated on the platform in real time.
telemedicine_diabetes
Telemedicine
Direct communication between patient and healthcare professional, by chat and video call.
follow-up_online_diabetes
Personalized follow-up
Improves individual and group treatment of patients thanks to data collected between visits.
Proven results
Controlled mean Glycosylated Hemoglobin
The average estimated* glycosylated haemoglobin of users with regular use of SocialDiabetes is 6.7% for type 1 and 6.5% for type 2.
results_hba1c_socialdiabetes
Reduction of up to 1% of Glycosylated Hemoglobin in 3 months
Users with type 1 diabetes with a high initial glycosylated haemoglobin (HbA1c > 8%), experience, on average, a reduction of 1% after 3 months of continuous use of SocialDiabetes. In the case of users with type 2 diabetes, this reduction rises to 2%.
reduccion_hba1c_socialdiabetes
Join the largest community of users.
Thanks to SocialDiabetes our users ...
carbohydrates_socialdiabetes
Have eaten more than 7 million servings of carbohydrates.
insulin_socialdiabetes
More than 141 liters of rapid insulin have been put in.
metformin_socialdiabetes
Have taken more than 205,000 pills
Awards
logo_wsa
Best mobile application in the health category - WSA United Nations
logo_foundation_isys
Best Health App 2015-2019 iSYS Foundation
logo_munichre
Winners MunichRE InsurTech Accelerator 2016
Collaborators
logo_menarini_diagnostics
logo_micelab
logo_munichre
logo_university_of_oxford
european_commission_logo
eit_logo
agamatrix
eu_logo
farmalisto_logo
einnovation_zed_logo
ascensia_logo
novo_nordisk_logo
NextGenerationEU
PROJECT: Towards a new generation of digital diabetes solutions: Artificial pancreas for patients with continuous monitoring devices and smart pen insulin. (2022 - 2025). Reference: CPP2021-008659. Funded by MCIN - 656.441,06€. P.I. Josep Vehí. Participants: SocialDiabetes, UdG
logo_NextGenerationEU